We must diversify, says new Glaxo boss

The new head of GlaxoSmithKline today said the drug giant must change to survive the growing threat of generic competition for its leading products.

Andrew Witty, who became chief executive in May, wants to create a more diversified global business to reduce GSK's dependence on a small number of drugs, boost productivity, and create a more cost-efficient company.